Troglitazone protects human erythrocytes from oxidant damage.

May JM, Qu ZC
Antioxid Redox Signal. 2000 2 (2): 243-50

PMID: 11229529 · DOI:10.1089/ars.2000.2.2-243

The antidiabetic drug troglitazone contains the active chromanol ring of alpha-tocopherol, which should give it antioxidant properties within cells. In these studies, the antioxidant effects of troglitazone were tested in human erythrocytes and in their ghosts. Troglitazone bound to erythrocyte ghosts in a linear manner and was retained even after centrifugation washes. In response to an oxidant stress generated by a water-soluble free radical initiator, troglitazone that was bound to erythrocyte ghosts was oxidized, but induced a lag-phase in the disappearance of endogenous alpha-tocopherol and in the appearance of lipid hydroperoxides. Troglitazone also delayed loss of endogenous alpha-tocopherol and hemolysis in washed intact erythrocytes in response to free radical-induced extracellular oxidant stress. To mimic exposure of erythrocytes to lipid hydroperoxides in vivo, erythrocytes were incubated with phospholipid liposomes that contained small amounts of preformed lipid hydroperoxides. This induced an oxidant stress in both the liposomes and cells. Troglitazone in concentrations above 4 microM almost completely prevented further appearance of lipid hydroperoxides in the liposomes, and also completely preserved alpha-tocopherol in the erythrocytes. The present results suggest that troglitazone will help to prevent peroxidative damage to erythrocytes in areas of excessive oxidant stress in the vascular bed.

MeSH Terms (16)

Antioxidants Cells, Cultured Chromans Dose-Response Relationship, Drug Erythrocyte Membrane Erythrocytes Free Radicals Humans Lipid Peroxides Liposomes Oxidative Stress Thiazoles Thiazolidinediones Time Factors Troglitazone Vitamin E

Connections (1)

This publication is referenced by other Labnodes entities: